公开(公告)号：EP3178928A1

公开(公告)日：2017-06-14

申请号：EP17152034.9

申请日：2014-08-07

申请人： Regeneron Pharmaceuticals, Inc. ,  President and Fellows of Harvard College

发明人： LAI, Ka-man Venus ,  GONG, Guochun ,  RINN, John ,  FRENDEWEY, David ,  VALENZUELA, David M

IPC分类号： C12N15/00 ,  C12N15/87 ,  A61K48/00 ,  A01K67/027 ,  C12Q1/68

CPC分类号： A01K67/0276 ,  A01K2217/075 ,  A01K2217/077 ,  A01K2227/105 ,  A01K2267/03 ,  A01K2267/0393 ,  A61D19/04 ,  C12Q1/6876 ,  C12Q2600/158 ,  C12Q2600/178

摘要： Genetically modified non-human animals are provided that exhibit a functional lack of one or more IncRNAs. Methods and compositions for disrupting, deleting, and/or replacing IncRNA-encoding sequences are provided. Genetically modified mice that age prematurely are provided. Also provided are cells, tissues and embryos that are genetically modified to comprise a loss-of-function of one or more IncRNAs.

摘要翻译： 提供了遗传修饰的非人动物，其表现出缺乏一种或多种IncRNA的功能。 提供了用于破坏，删除和/或替换IncRNA编码序列的方法和组合物。 提供过早老化的基因修饰小鼠。 还提供了经遗传修饰以包含一种或多种IncRNA的功能丧失的细胞，组织和胚胎。

公开(公告)号：EP2221065B1

公开(公告)日：2016-12-28

申请号：EP08855467.0

申请日：2008-11-21

申请人： Japan Science and Technology Agency

发明人： SHINDO, Takayuki

IPC分类号： A61K48/00 ,  A61K38/00 ,  A61P1/00 ,  A61P3/00 ,  A61P3/04 ,  A61P3/08 ,  A61P3/10 ,  A61P9/00 ,  A61P9/10 ,  A61P9/12 ,  C12Q1/02 ,  C12Q1/68 ,  G01N33/15 ,  G01N33/50 ,  C12N15/09

CPC分类号： G01N33/6872 ,  A01K67/0276 ,  A01K2217/077 ,  A01K2217/15 ,  A01K2217/206 ,  A01K2227/105 ,  A01K2267/035 ,  A01K2267/0375 ,  A61K38/00 ,  A61K48/00 ,  C07K14/705 ,  C12N15/8509 ,  C12Q1/6883 ,  G01N2500/00 ,  G01N2800/04 ,  Y10T436/143333

公开(公告)号：EP2801369A1

公开(公告)日：2014-11-12

申请号：EP13305592.1

申请日：2013-05-06

申请人： Centre National de la Recherche Scientifique ,  Université d'Aix-Marseille

发明人： Moqrich, Aziz ,  Delfini, Marie-Claire ,  Mantilleri, Annabelle

IPC分类号： A61K38/17

CPC分类号： A61K38/1709 ,  A01K67/0276 ,  A01K2217/077 ,  A01K2227/105 ,  A01K2267/0356 ,  C07K14/47

摘要： The present invention relates to novel compounds for use for preventing, alleviating or treating pain in a subject. Also herein described are pharmaceutical compositions, their preparation and uses as well as methods for preventing, alleviating or treating pain using such compounds and compositions.

摘要翻译： 本发明涉及用于预防，缓解或治疗受试者疼痛的新化合物。 本文还描述了药物组合物，其制备和用途以及使用这些化合物和组合物预防，缓解或治疗疼痛的方法。

公开(公告)号：EP2031062B1

公开(公告)日：2018-10-24

申请号：EP07742485.1

申请日：2007-04-26

申请人： The University of Tokyo

发明人： YAMANASHI, Yuji ,  HIGUCHI, Osamu ,  OKADA, Kumiko ,  INOUE, Akane

IPC分类号： C12N15/12 ,  A01K67/027 ,  A61K38/00 ,  A61K48/00 ,  C07K14/435 ,  C07K16/40 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12Q1/48 ,  C12Q1/68 ,  G01N33/15 ,  G01N33/50 ,  G01N33/53 ,  A61P25/00

CPC分类号： C07K14/4702 ,  A01K67/0276 ,  A01K2217/075 ,  A01K2217/077 ,  A01K2227/105 ,  A01K2267/03 ,  A01K2267/035 ,  A61K38/00 ,  C07K16/18 ,  C12N9/1205 ,  C12N15/8509 ,  G01N33/6887 ,  G01N2333/9121 ,  G01N2800/2878 ,  G01N2800/385

摘要： Disclosed are DNA encoding a polypeptide which can modulate the activity of a muscle-specific tyrosine kinase, and others. The DNA is selected from the following members (a) to (d): (a) DNA comprising a specific nucleotide sequence; (b) DNA comprising a nucleotide sequence capable of hybridizing with a specific nucleotide sequence under stringent conditions; (c) DNA comprising a nucleotide sequence encoding an amino acid sequence having the substitution, deletion and/or addition of one or several amino acid residues in a specific amino acid sequence; and (d) DNA comprising a nucleotide sequence having 90% or higher homology to a specific nucleotide sequence.

公开(公告)号：EP3030653A2

公开(公告)日：2016-06-15

申请号：EP14834544.0

申请日：2014-08-07

申请人： Regeneron Pharmaceuticals, Inc. ,  President and Fellows of Harvard College

发明人： LAI, Ka-man Venus ,  GONG, Guochun ,  RINN, John ,  FRENDEWEY, David ,  VALENZUELA, David M.

IPC分类号： C12N15/00 ,  C12N15/87 ,  A61K48/00

CPC分类号： A01K67/0276 ,  A01K2217/075 ,  A01K2217/077 ,  A01K2227/105 ,  A01K2267/03 ,  A01K2267/0393 ,  A61D19/04 ,  C12Q1/6876 ,  C12Q2600/158 ,  C12Q2600/178

摘要： Genetically modified non-human animals are provided that exhibit a functional lack of one or more lncRNAs. Methods and compositions for disrupting, deleting, and/or replacing lncRNA-encoding sequences are provided. Genetically modified mice that age prematurely are provided. Also provided are cells, tissues and embryos that are genetically modified to comprise a loss-of-function of one or more lncRNAs.

摘要翻译： 提供了表现出缺乏一种或多种IncRNA功能的转基因非人动物。 提供了用于破坏，缺失和/或替换IncRNA编码序列的方法和组合物。 提供过早的转基因小鼠。 还提供了经遗传修饰以包含一种或多种IncRNA的功能丧失的细胞，组织和胚胎。

公开(公告)号：EP2665822A1

公开(公告)日：2013-11-27

申请号：EP12702103.8

申请日：2012-01-18

申请人： Amgen Inc.

发明人： GINGRAS, Jacinthe ,  MCDONOUGH, Stefan I.

IPC分类号： C12N15/85 ,  A01K67/027 ,  C07K16/00 ,  A61K49/00 ,  G01N33/50

CPC分类号： C12N15/8509 ,  A01K67/0276 ,  A01K2217/077 ,  A01K2227/105 ,  A01K2267/03 ,  A61K49/0008 ,  C07K16/00

摘要： A viable global NaV1.7−/− knockout mouse is disclosed, and a breeding colony of global NaV1.7−/− knockout mice. Also disclosed are an isolated mouse gamete that does not encode a functional NaV1.7−/−, produced by the NaV1.7−/− knockout mouse; an isolated NaV1.7−/− mouse cell, or a progeny cell thereof, isolated from the NaV1.7−/− knockout mouse; and a primary cell culture or a secondary cell line and a tissue or organ explant or culture thereof derived from the NaV1.7−/− knockout mouse. Disclosed also are a hybridoma, wherein the hybridoma was originally formed from the fusion of the isolated NaV1.7−/− mouse cell mouse cell and a myeloma cell, and a method of making an antibody. Also disclosed are assays useful for screening prospective NaV1.7 inhibitors and dose ranging a test NaV17 inhibitor compound, which were validated using the NaV1.7−/− knockout mouse.

公开(公告)号：EP2419133A1

公开(公告)日：2012-02-22

申请号：EP10713931.3

申请日：2010-04-13

申请人： Deutsches Krebsforschungszentrum ,  Galapagos S.A.S.U.

发明人： RAWADI, Georges ,  NIEHRS, Christof

IPC分类号： A61K39/395 ,  C07K16/18 ,  A61P19/08

CPC分类号： C07K16/18 ,  A01K67/0276 ,  A01K2217/077 ,  A01K2227/105 ,  A01K2267/035 ,  C07K14/47 ,  C12N15/8509 ,  G01N33/6893 ,  G01N2800/10 ,  G01N2800/108

摘要： The present invention relates to uses of antagonists of Rspondin-3 (Rspo3) polypeptides or Rspondin-3 nucleic acids. The invention is based on the demonstration that partial deficiency of Rspo3 leads to a significant increase of bone mass. These results indicate a major role for Rspo3 as a bone anabolic marker or target. Thus, the invention also relates to the use of Rspo3 antagonists in the treatment of osteopenia disorders, particularly in conditions associated with increased bone resorption.

公开(公告)号：EP2354159A1

公开(公告)日：2011-08-10

申请号：EP10001208.7

申请日：2010-02-05

申请人： RWTH Aachen

发明人： Zernecke, Alma, Dr. ,  Weber, Christian, Dr.

IPC分类号： C07K16/24 ,  C07K14/52 ,  C07K14/775

CPC分类号： C07K16/24 ,  A01K67/0276 ,  A01K2217/075 ,  A01K2217/077 ,  A01K2227/105 ,  A01K2267/0375 ,  A61K2039/505 ,  C07K14/52 ,  C07K14/775 ,  C07K2317/76 ,  C12N15/8509

摘要： The present invention is based on the studies of the pathogenic role of CCL17-expressing DCs and their effector function in inflammatory diseases, particularly in atherosclerotic diseases. It relates to agents inhibiting the binding reaction between a CCL17 cytokine and a CCL17 receptor for use as a medicament ( Fig. 5a ).

摘要翻译： 本发明基于对表达CCL17的DC的致病作用及其在炎性疾病，特别是动脉粥样硬化疾病中的效应功能的研究。 它涉及抑制CCL17细胞因子和CCL17受体之间的结合反应以用作药物的药剂（图5a）。

公开(公告)号：EP3030653A4

公开(公告)日：2017-07-26

申请号：EP14834544

申请日：2014-08-07

申请人： REGENERON PHARMA ,  HARVARD COLLEGE

发明人： LAI KA-MAN VENUS ,  GONG GUOCHUN ,  RINN JOHN ,  FRENDEWEY DAVID ,  VALENZUELA DAVID M

IPC分类号： C12N15/00 ,  A01K67/027 ,  A61K48/00 ,  C12N15/87

CPC分类号： A01K67/0276 ,  A01K2217/075 ,  A01K2217/077 ,  A01K2227/105 ,  A01K2267/03 ,  A01K2267/0393 ,  A61D19/04 ,  C12Q1/6876 ,  C12Q2600/158 ,  C12Q2600/178

公开(公告)号：EP3004345A4

公开(公告)日：2017-02-15

申请号：EP14804562

申请日：2014-04-29

申请人： RECOMBINETICS INC

发明人： CARLSON DANIEL F ,  FAHRENKRUG SCOTT C

IPC分类号： C12N15/00 ,  A01K67/027 ,  C12N5/00 ,  C12N15/02 ,  C12N15/85

CPC分类号： A01K67/0276 ,  A01K67/0273 ,  A01K2217/077 ,  A01K2227/101 ,  A01K2227/103 ,  A01K2227/108 ,  A01K2267/02 ,  C12N15/8509 ,  C12N2800/30 ,  C12N2800/80

摘要： A genetically modified livestock animal, and methods of making and using the same, the animal comprising a genetic modification to disrupt a target gene selectively involved in gametogenesis, wherein the disruption of the target gene prevents formation of functional gametes of the animal. Animals that create progeny with donor genetics, and methods of making and using the same. Cells, and methods of making and using the cells, with a genetic modification to disrupt a target gene selectively involved in gametogenesis.